May & Baker Nigeria Plc (MAYBAK.ng) 2022 Abridged Report
May & Baker Nigeria Plc (MAYBAK.ng) listed on the Nigerian Stock Exchange under the Pharmaceuticals sector has released it’s 2022 abridged results.
For more information about May & Baker Nigeria Plc (MAYBAK.ng) reports, abridged reports, interim earnings results and earnings presentations visit the May & Baker Nigeria Plc (MAYBAK.ng) company page on AfricanFinancials.
Indicative Share Trading Liquidity
The total indicative share trading liquidity for May & Baker Nigeria Plc (MAYBAK.ng) in the past 12 months, as of 3rd January 2023, is US$849.61K (NGN358.71M). An average of US$70.8K (NGN29.89M) per month.
May & Baker Nigeria Plc 2022 abridged results
Company Profile
May & Baker Nigeria Plc manufactures and markets a range of pharmaceuticals, vaccines, medical diagnostics, foods and consumer healthcare products in Nigeria. Pharmaceutical products include anti-diabetics, anti-infectives, anti-malaria, analgesics, cough & cold treatments, multivitamins and anxiolytics. May & Bake Nigeria Plc produce a range of Mimee noodles and Lily still water. The company’s head office is in Lagos, Nigeria. May & Baker Nigeria Plc is listed on the Nigerian Stock Exchange
Recent Documents & News
-
Interim Reports
May & Baker Nigeria Plc (MAYBAK.ng) Q12023 Interim Report – April 28, 2023 -
Annual Reports
May & Baker Nigeria Plc (MAYBAK.ng) 2022 Annual Report – March 29, 2023 -
Corporate announcement, Dividends
May & Baker Nigeria Plc declares a final dividend of 0.3 NGN per share – March 27, 2023 -
Interim Reports
May & Baker Nigeria Plc (MAYBAK.ng) Q32022 Interim Report – October 28, 2022 -
Interim Reports
May & Baker Nigeria Plc (MAYBAK.ng) HY2022 Interim Report – July 29, 2022
